Replimune Group (NASDAQ:REPL) Sets New 12-Month High After Analyst Upgrade

Shares of Replimune Group, Inc. (NASDAQ:REPL) reached a new 52-week high during mid-day trading on Friday after BMO Capital Markets raised their price target on the stock from $14.00 to $18.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $15.46 and last traded at $15.34, with a volume of 794946 shares trading hands. The stock had previously closed at $11.05.

REPL has been the topic of a number of other research reports. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a report on Friday. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Finally, Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and an average target price of $17.00.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently made changes to their positions in REPL. Nisa Investment Advisors LLC boosted its position in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Replimune Group in the second quarter worth about $57,000. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the third quarter worth about $133,000. Arizona State Retirement System acquired a new position in shares of Replimune Group during the second quarter valued at about $108,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after purchasing an additional 5,926 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Stock Up 44.2 %

The business’s 50 day moving average is $11.51 and its 200 day moving average is $9.67. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -5.22 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Sell-side analysts anticipate that Replimune Group, Inc. will post -3.02 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.